创新医药行业周报：干细胞药物实现突破

财通证券01-08 00:00

近期，中美两国药监部门均批准了干细胞疗法产品上市。1 月2 日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市，用于治疗14 岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病（aGVHD）。2024 年12 月，美国FDA 批准了同种异体骨髓来源的间充质干细胞(MSC)疗法Ryoncil(Remestemcel-L)上市，用于治疗2 个月及以上儿童患者的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2501791240?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-08 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2501791240","market":"sh","top_or_hot":-1,"title":"创新医药行业周报：干细胞药物实现突破","media":"财通证券","content":"<div>\n<p>近期，中美两国药监部门均批准了干细胞疗法产品上市。1 月2 日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市，用于治疗14 岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病（aGVHD）。2024 年12 月，美国FDA 批准了同种异体骨髓来源的间充质干细胞(MSC)疗法Ryoncil(Remestemcel-L)上市，用于治疗2 个月及以上儿童患者的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108125130aba2a582&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创新医药行业周报：干细胞药物实现突破</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创新医药行业周报：干细胞药物实现突破\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108125130aba2a582&s=b><strong>财通证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近期，中美两国药监部门均批准了干细胞疗法产品上市。1 月2 日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市，用于治疗14 岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病（aGVHD）。2024 年12 月，美国FDA 批准了同种异体骨髓来源的间充质干细胞(MSC)疗法Ryoncil(Remestemcel-L)上市，用于治疗2 个月及以上儿童患者的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108125130aba2a582&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0102","symbol_name":"重组","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108125130aba2a582&s=b","article_id":"2501791240","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108125130aba2a582&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501791240","pubTimestamp":1736265600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近期，中美两国药监部门均批准了干细胞疗法产品上市。1 月2 日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市，用于治疗14 岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病。干细胞适应症广泛：干细胞所针对的适应症可以涵盖肺部疾病、消化系统疾病、肝脏疾病、神经系统疾病、呼吸系统疾病等，同时也涵盖了糖尿病、骨质疏松、系统性红斑狼疮。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600721":"百花医药","BK0102":"重组","BK0216":"研究试验"},"translate_title":"Innovative Pharmaceutical Industry Weekly Report: Stem Cell Drugs Achieve Breakthrough","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600721":0.9},"content_text":"近期，中美两国药监部门均批准了干细胞疗法产品上市。1 月2 日，国家药监局通过优先审评审批程序附条件批准我国首款干细胞治疗药品艾米迈托赛注射液上市，用于治疗14 岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病（aGVHD）。2024 年12 月，美国FDA 批准了同种异体骨髓来源的间充质干细胞(MSC)疗法Ryoncil(Remestemcel-L)上市，用于治疗2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病(SR-aGVHD)，这也是首款获得FDA 批准上市的MSC 疗法。干细胞适应症广泛：干细胞所针对的适应症可以涵盖肺部疾病、消化系统疾病、肝脏疾病、神经系统疾病、呼吸系统疾病等，同时也涵盖了糖尿病、骨质疏松、系统性红斑狼疮。广泛的适应症也是基于干细胞强大的再生与修复能力，且干细胞还可以通过分泌生长因子和细胞因子等活性物质，调节炎症反应和免疫反应，从而进一步促进组织的修复和功能的恢复。投资建议：持续看好医药上市公司中具有显著创新属性的公司，建议关注海创药业、诺诚健华、迈威生物、泽璟制药、百奥泰、微芯生物、艾力斯、华东医药、恒瑞医药、信立泰、特宝生物、科伦博泰、康方生物、信达生物、中源协和、诚达药业和亚盛药业等。风险提示：集采压力大于预期风险；产品研发进度不及预期风险；竞争加剧风险；政策监管环境变化风险；药物研发服务市场需求下降的风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501791240"}